MDT-AP-2031
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- S1
- umap1_2d
- -0.637669317
- umap2_2d
- -10.55550929
- umap1_3d
- -3.329078096
- umap2_3d
- -0.743642253
- umap3_3d
- 6.205376041
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.340
- BILE_ACID_METABOLISM+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- INTERFERON_GAMMA_RESPONSE+0.250
- UV_RESPONSE_DN+0.230
- PANCREAS_BETA_CELLS+0.180
- TNFA_SIGNALING_VIA_NFKB+0.150
- APOPTOSIS+0.140
- CHOLESTEROL_HOMEOSTASIS+0.140
- APICAL_SURFACE+0.130
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.370
- MYC_TARGETS_V2-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- E2F_TARGETS-0.210
- G2M_CHECKPOINT-0.200
- MITOTIC_SPINDLE-0.190
- MYC_TARGETS_V1-0.190
- PI3K_AKT_MTOR_SIGNALING-0.170
- ADIPOGENESIS-0.150
- DNA_REPAIR-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0827 | Med | Medulloblastoma | 0.754 |
| 2 | MNG213 | — | — | 0.745 |
| 3 | MNG18 | — | — | 0.732 |
| 4 | 20050088.Her2HRpos | — | A | 0.722 |
| 5 | TCGA-D8-A27T-01A-11R-A16F-07 | — | A | 0.714 |
| 6 | BS_N5B2CZMH | pilocytic astrocytoma | — | 0.707 |
| 7 | SRR1435901 | GTEX | — | 0.707 |
| 8 | SRR820379 | GTEX | — | 0.699 |
| 9 | SRR10842365 | — | — | 0.697 |
| 10 | SRR1346670 | GTEX | — | 0.694 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |